Ziopharm Oncology Announces Publication of Positive Results of Phase 1 Monotherapy Trial of Controlled IL-12 in Patients with Recurrent Glioblastoma in Science Translational Medicine

NEXT STORY
Y-mAbs Announces Second Quarter 2019 Financial Results and Recent Corporate Developments
PREV STORY
Clinical Trial ‘Solutions’ Account for 40% of Global Spending on eCOA, eSource & Clinical Trials, Finds Fact.MR
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

AlloSure data will be presented at ASN

BRISBANE, Calif., Oct. 30, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company ...

author_avatar
NASDAQ Market News

ChemoCentryx Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights

author_avatar
NASDAQ Market News

Isothermal Nucleic Acid Amplification Technology (INAAT) Market Analysis, Trends, and Forecasts, 2019-2025 – Market to Witness Healthy Growth, Driven by Low-cost Advantages

author_avatar
NASDAQ Market News